42374-78-7

Usage

Uses

Used in Chemical Research:
(4-(dimethylamino)phenyl)(pyridin-3-yl)methanone is used as a research compound for exploring its basic properties and potential reactivity in organic reactions due to its dimethylamino group.
Used in Pharmaceutical Research:
In the pharmaceutical industry, (4-(dimethylamino)phenyl)(pyridin-3-yl)methanone is used as a starting material or intermediate in the development of new drugs, leveraging its potential to interact with biological systems.
Used in Synthesis of Organic Compounds:
(4-(dimethylamino)phenyl)(pyridin-3-yl)methanone is utilized as a building block in the synthesis of more complex organic molecules, taking advantage of its aromatic nature and carbonyl group.
Used as a pH Indicator:
Owing to its basic nature, (4-(dimethylamino)phenyl)(pyridin-3-yl)methanone is used as a pH indicator to measure the acidity or alkalinity of solutions in various applications, including educational, research, and industrial settings.
Used as a Catalyst in Organic Reactions:
(4-(dimethylamino)phenyl)(pyridin-3-yl)methanone serves as a catalyst to facilitate and speed up organic reactions, particularly those involving the formation or breaking of chemical bonds, which is valuable in the production of pharmaceuticals, agrochemicals, and other specialty chemicals.

Upstream product

• 619-84-1 p-N,N-dimethylaminobenzoic acid 
• 626-55-1 3-Bromopyridine 
• 212956-18-8 N-methoxy-N-methyl p-(dimethylamino)benzamide 

Downstream Products

• 1374584-18-5 (4-trifluoromethylphenyl)(4-dimethylaminophenyl)pyrid-3-yl methanol 

Relevant academic research and scientific papers

METHYLENE LINKED QUINOLINYL MODULATORS OF RORyt

The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.

Analogues of fenarimol are potent inhibitors of trypanosoma cruzi and are efficacious in a murine model of chagas disease

We report the discovery of nontoxic fungicide fenarimol (1) as an inhibitor of Trypanosoma cruzi (T. cruzi), the causative agent of Chagas disease, and the results of structure-activity investigations leading to potent analogues with low nM IC50s in a T. cruzi whole cell in vitro assay. Lead compounds suppressed blood parasitemia to virtually undetectable levels after once daily oral dosing in mouse models of T. cruzi infection. Compounds are chemically tractable, allowing rapid optimization of target biological activity and drug characteristics. Chemical and biological studies undertaken in the development of the fenarimol series toward the goal of delivering a new drug candidate for Chagas disease are reported.